What is the CA-62 tumour marker?
CA-62 is a multi-cancer early detection (MCED) blood test based on a marker of poorly differentiated cells. The test measures the total level of membrane proteins carrying a distinctive N-glycosylation pattern, which enter the bloodstream when cells divide rapidly, including cancer cells. The test system is registered by Roszdravnadzor in Russia, certificate No. RZN 2020/9880.
What is the normal range for CA-62?
Up to and including 5,000 U/mL. Results of 95% of clinically healthy people fall within this range. A result above 5,000 U/mL requires a repeat test within 4–8 weeks and evaluation by a physician together with other findings.
Can I compare two CA-62 results with each other?
Only with a physician. CA-62 is measured by a competitive assay: the more marker in the blood, the weaker the light signal the analyser reads. At around 1,000 U/mL the signal is in the order of a million units; above 7,000 U/mL it is only in the hundreds. So numbers that look close can differ greatly in signal: 4,500 and 5,500 U/mL differ in luminescence by about a hundredfold. A result is assessed against the 5,000 U/mL cut-off, and changes over time are assessed by a physician.
Does an elevated CA-62 mean I have cancer?
No. An isolated elevation of CA-62 is not a diagnosis. The marker responds to any rapid cell division: inflammation and infection, immune response after vaccination, recovery from blood loss, pregnancy. Temporary causes resolve, so the test is repeated in 4–8 weeks. If the level stays high, a physician orders further examination.
Does inflammation raise CA-62?
Not by itself. The marker responds not to inflammatory proteins but to active cell division, such as stem cells producing antibodies and immune cells during an acute process. So a temporary rise is possible with acute inflammation, infection or an exacerbation of a chronic disease. In chronic inflammatory diseases in remission, an elevated level occurs in no more than 5% of cases; in autoimmune diseases it is more common, up to half of cases (in psoriasis only in isolated cases). With cancer the elevation does not resolve on its own, so the test is repeated after 30–60 days and the history is taken into account.
Should CA-62 be part of an annual check-up without symptoms?
Yes. CA-62 is a non-organ-specific signal: it reflects the accumulation of cells with signs of poor differentiation and can point to a process before its location is known. It does not replace organ-specific examinations and tumour markers but complements them — these methods answer different questions. Among apparently healthy people, a result above 5,000 U/mL occurs in about 3% under 40, 5% at 45–60 and 6% over 55; in that case the test is repeated after 30–60 days.
How is CA-62 different from conventional tumour markers (CEA, CA 15-3, PSA)?
The signal of conventional tumour markers depends on tumour size, so they often stay normal at early stages. The CA-62 signal depends on the metabolic activity of tumour cells: an elevated level has been described with tumours as small as 5 mm. That is why CA-62 sensitivity is already high at stage I–II: 89–94% across six carcinoma types, compared with 15–56% for conventional markers in comparative data.
Which cancers does CA-62 detect?
Diagnostic accuracy is statistically confirmed for carcinomas of the breast, prostate, lung, ovary, kidney and colon/rectum, which together account for nearly half of all cancer deaths in Russia. Early detection cases have been described across almost the entire tumour spectrum, including choroidal melanoma. Sarcomas are not detected, and tumours with a low cell division rate (low Ki-67 index) are detected later.
Who should take the CA-62 test?
According to the instructions for use, the test is intended to help a physician decide on further examination. It is used in annual check-ups, screening programmes and to monitor patients during and after treatment. Discuss the test and your result with a physician.
How reliable is a normal result?
A result of up to and including 5,000 U/mL lowers the probability of aggressive cancer by about 10 times. For people around 55 years old, the estimated negative predictive value of the test is about 99.9%. In other words, of 1,000 people that age about 10 have cancer, and in about one of them it may go undetected in the current year.
How much does the CA-62 test cost?
In Russia, from 8,000 RUB at partner laboratories, before discounts. Check the exact price on the laboratory's website.
Where can I take the CA-62 test?
In Russia, at Citilab and DNKOM laboratories in more than 250 cities. Clinics and partners outside Russia can contact us at info@oncomarker.ru.